CXCR2 and hepatocellular carcinoma: Future clinical trials should consider concurrent or sequential application of neutrophil-targeting therapies with ICIs, such as CXCR2 inhibition, PAD4 inhibition, or COX-2 combination therapy, supplemented by measures like immune profiling and single-cell sequencing analysis, to enhance the efficacy of HCC immunotherapy.